Application of pseudolaric acid in preparation of antiplatelet drugs

An anti-platelet drug, the technology of hibiscus bark acetic acid, applied in the field of medicine and biology, can solve the problems such as no report on the activity of hibiscus bark acetic acid, and achieve the effect of inhibiting platelet aggregation, inhibiting platelet aggregation, and simple preparation process

Active Publication Date: 2021-08-13
FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the activity of hibiscus bark acetic acid in antiplatelet and thrombus aspects in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pseudolaric acid in preparation of antiplatelet drugs
  • Application of pseudolaric acid in preparation of antiplatelet drugs
  • Application of pseudolaric acid in preparation of antiplatelet drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Azalea acetic acid inhibits collagen-induced aggregation of human platelets in vitro.

[0029] (1) Source of experimental human platelets Healthy volunteers signed informed consent for blood donation and were given certain nutritional subsidies. Venous whole blood was collected, apheresis platelets were separated by Kunming Blood Center, and apheresis platelets were collected in the Hematology Department of the First Affiliated Hospital of Kunming Medical University.

specific Embodiment approach

[0031] Step 1, using DMSO to dissolve and adjust the concentration of hibiscus bark acetic acid to 1.5mM and 1M.

[0032] Step 2, washing the platelets. Take 1mL human apheresis platelets stored at 25°C with constant temperature and shaking in a 1.5mL centrifuge tube, add EDTA at a final concentration of 5mM and 0.1U / mL Apyrase (prepared with normal saline to prevent platelet aggregation during centrifugation), and centrifuge at room temperature at 400g 10 minutes; discard the supernatant of the centrifuged human apheresis platelets, add 1mL Tyrode's Buffer B (137mM NaCl, 27mM KCl, 1mM MgCl 2 , 0.42mM NaH 2 PO 4 , 5.5mM Glucose, 5.55mM HEPES, 0.25% Bovine Serum Albumin, pH 6.5), 5mM EDTA, 0.1U / mL Apyrase, blow gently, centrifuge again at 400g room temperature for 10 minutes; MgCl 2 ,0.42mM NaH 2 PO 4 , 5.5mM Glucose, 5.55mM HEPES, 0.25% Bovine Serum Albumin, pH 7.4) resuspend the centrifuged platelets, and adjust the platelet count to 150-250×10 9 / L. Store with shakin...

Embodiment 2

[0036] Hibiscus bark acetic acid inhibits platelet clot retraction.

[0037] (1) The source of experimental human platelets is the same as in Example 1.

[0038] (2) The specific implementation method is as follows:

[0039] Platelet-rich plasma was diluted with Tyrode's Buffer A and quantified to 500×10 9 / L, put 200 μL of platelet-rich plasma into a siliconized transparent glass tube, and incubate at 37°C for 20 minutes. Use DMSO to dissolve hibiscus acetic acid, and adjust the concentration to 1M. The experimental groups were: positive control group (Thrombin 0.2U / mL), negative control group (Control) and hibiscus bark acetic acid experimental group. Add hibiscus bark acetic acid with a final concentration of 10 mM in the experimental group, add DMSO equal to the volume of the experimental group in the positive control group and negative control group, and incubate at 37° C. for 20 minutes. After incubation, add thrombin at a final concentration of 0.2 U / mL to the posit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of pseudolaric acid in preparation of antiplatelet drugs, and belongs to the technical field of medical biology. Antiplatelet is anti-collagen-induced platelet aggregation or anti-thrombin-induced platelet blood clot retraction, and an optical turbidimetry detection result shows that pseudolaric acid has a remarkable inhibition effect on collagen-induced human platelet aggregation and thrombin-induced platelet blood clot retraction; and pseudolaric acid is not limited to inhibition of collagen-induced platelet aggregation, can be used for the influence of the pseudolaric acid and other platelet activators (collagen, arachidonic acid, ADP, epinephrine, Ristocetin and the like) on the action and related functions of platelets, and can also be used for monitoring existing anti-platelet treatment.

Description

technical field [0001] The invention belongs to the technical field of medicine and biology, and in particular relates to the application of hibiscus bark acetic acid in the preparation of antiplatelet drugs. [0002] technical background [0003] Unstable coronary artery plaque rupture and erosion, secondary platelet aggregation, vasospasm contraction, and thrombosis caused by myocardial infarction are the leading causes of death in the United States and other developed industrialized countries. More than 40%. Platelets play an important role in arterial thrombosis. The classic antiplatelet drug aspirin and the new drug abciximab, which blocks the combination of αIIbβ3 and fibrinogen, have played an important role in clinical treatment, but there are also gastrointestinal reactions and Potential risks such as bleeding. The development of antiplatelet drugs with better safety and efficacy has important clinical and social value. [0004] Vascular endothelial cells are dama...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61K36/15A61P7/02
CPCA61K31/366A61K36/15A61P7/02
Inventor 孟照辉叶雨佳彭云珠石少卿李朝中王华炜蒙超柴圣杰
Owner FIRST AFFILIATED HOSPITAL OF KUNMING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap